For Immediate Release
Gene Delivery of Drugs Directly into Arthritic Joints Is Making the Leap to Patients
Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com
New Rochelle, NY, January 22, 2018—Localized gene delivery to diseased joints to achieve sustained drug production at the site of osteoarthritis or rheumatoid arthritis is gaining momentum, with clinical trials underway in the U.S. and the first arthritis gene therapy recently approved in Korea. A detailed review of current trends in the field, gene delivery strategies, and ongoing clinical trials and product development are presented in an article published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website until February 22, 2018.
The article "Gene Delivery to Joints by Intra-Articular Injection" is coauthored by Christopher Evans, Mayo Clinic (Rochester, MN), Steven Ghivizzani, University of Florida College of Medicine (Gainesville, FL), and Paul Robbins, The Scripps Research Institute (Jupiter, FL). The authors describe the advantages of using gene therapy for localized drug delivery to the joints, including higher drug concentrations at the site of disease and reduced exposure to nontarget organs. They discuss the factors that contribute to selection of a therapeutic transgene and an optimal delivery vector, and review the human clinical trials for arthritis gene therapy in the U.S. that have taken place and are ongoing or pending.
“Arthritis is the most common disorder that is likely to be treatable with gene therapy within the next several years,” says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "This latest installment of our Target Organ series provides a comprehensive review of the optimal platforms for treating these potentially disabling disorders."
Research reported in this publication was supported by the National Institutes of Health under Award Numbers R01 AR43623 R21 AR049606, R01 AR048566, R01 AR057422, and R01 AR051085. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101